Abbott Laboratories (ABT) : Johnson Investment Counsel Inc scooped up 88,092 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 969,086 shares of Abbott Laboratories which is valued at $43,647,633.Abbott Laboratories makes up approximately 1.37% of Johnson Investment Counsel Inc’s portfolio.
Other Hedge Funds, Including , Cannell Peter B Co Inc boosted its stake in ABT in the latest quarter, The investment management firm added 121,340 additional shares and now holds a total of 717,704 shares of Abbott Laboratories which is valued at $32,325,388. Abbott Laboratories makes up approx 1.13% of Cannell Peter B Co Inc’s portfolio.Gardiner Nancy B boosted its stake in ABT in the latest quarter, The investment management firm added 2,835 additional shares and now holds a total of 9,435 shares of Abbott Laboratories which is valued at $425,047. Abbott Laboratories makes up approx 1.33% of Gardiner Nancy B’s portfolio.Private Capital Management Inc boosted its stake in ABT in the latest quarter, The investment management firm added 6,600 additional shares and now holds a total of 10,300 shares of Abbott Laboratories which is valued at $466,178. Abbott Laboratories makes up approx 0.44% of Private Capital Management Inc’s portfolio. James Investment Research Inc sold out all of its stake in ABT during the most recent quarter. The investment firm sold 405 shares of ABT which is valued $17,046.Hartford Financial Management reduced its stake in ABT by selling 102 shares or 0.18% in the most recent quarter. The Hedge Fund company now holds 57,698 shares of ABT which is valued at $2,429,086. Abbott Laboratories makes up approx 1.41% of Hartford Financial Management’s portfolio.
Abbott Laboratories closed down -0.27 points or -0.61% at $43.9 with 74,01,381 shares getting traded on Tuesday. Post opening the session at $44.37, the shares hit an intraday low of $43.9 and an intraday high of $44.42 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.